2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Gene Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3199 FLT3-ITD drives apoptosis blockade and venetoclax resistance in NPM1-mutated AML through BCAT1-mediated aatk/p53 suppression

Kainan Zhang, PhD, Xiaoxuan Lu2, Xiaohang ??? Ma3, Hao Jiang4, Qian Jiang Jr, MD5, Ying-Jun Chang6, Xiaojun Huang, MD,PhD7, Xiaosu Zhao8
1 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
2 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
3 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
4 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
5 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
6 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
7 Frontiers Science Center for Cancer Integrative Omics, Beijing, China, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies,Peking University, Beijing, China
8 Collaborative Innovation Center of Hematology, Peking University, Beijing, China, Peking University People's Hospital Molecular Diagnostics Center, Beijing, China, Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China, Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, 2019RU029, Beijing, China

NPM1 mutations are present in approximately 30% of adult acute myeloid leukemia (AML) cases, and concurrent FLT3-ITD mutations (NPM1mutFLT3ITD) confer an unfavorable prognosis. However, the previously used FLT3-ITD allelic ratio (AR) fails to provide accurate risk stratification for double-mutant patients. In our previous study aimed at identifying novel prognostic biomarkers for NPM1mutFLT3ITD subgroup, we found that branched-chain amino acid transferase 1 (BCAT1) expression was significantly higher in NPM1mutFLT3ITD patients than in those with NPM1 mutation alone, and associated with inferior outcomes. BCAT1 is a key regulator of branched-chain amino acid metabolism and suppresses DNA demethylase TET2 activity by reducing α-ketoglutarate (α-KG) levels. Through reduced representation bisulfite sequencing (RRBS) and RNA-seq, our prior studies identified apoptosis-associated tyrosine kinase (AATK) as a potential target of BCAT1-mediated methylation. Herein, we further explored how the BCAT1/AATK axis drives the poor prognosis of NPM1mutFLT3ITD AML.

We confirmed a positive correlation between TET2 and AATK expression in the TCGA database. Analysis of GSE218227 datasets also demonstrated that enhanced TET2 activity upregulates AATK expression in AML cells. We generated FLT3-ITD mutation in NPM1-mutated OCI-AML3 cells (NPM1mutFLT3ITD cells), and found the treatment with azacitidine (AZA) and dimethyl-α-KG (DM-α-KG) both significantly enhanced AATK expression through reduced promoter methylation in NPM1mutFLT3ITD cells. Knockdown of AATK by siRNA in OCI-AML3 cells significantly promoted cell proliferation. Meanwhile, AATK silencing reversed the proliferation impairment induced by 48-hour BCAT1 inhibitor pretreatment in NPM1mutFLT3ITD cells. Previous studies have demonstrated that AATK phosphorylates TP53 at Ser366, a residue that modulates the stability of TP53 binding to downstream molecules. We also found a positive correlation between AATK and the TP53 downstream molecules BAX and APAF1 through TCGA database, whereas BCAT1 showed negative correlation with these genes. In BCAT1-overexpressing and FLT3-ITD-transduced OCI-AML3 cells, Western blot demonstrated that phosphorylation of TP53 at Ser366 and expression of BAX and APAF1 were markedly reduced, whereas treatment with BCAT1 or FLT3 inhibitors restored their expression.

Given the known venetoclax resistance in NPM1mutFLT3ITD AML, we next explored whether the BCAT1/AATK/TP53 axis contributes to this process. Cell viability assays demonstrated that combined BCAT1 inhibitor and venetoclax treatment significantly reduced the viability of NPM1mutFLT3ITD cells compared to venetoclax alone. Synergy analysis revealed strong synergistic interaction between the BCAT1 inhibitor and venetoclax. qPCR analysis confirmed that AATK expression was upregulated following drug treatments. Notably, the combination of BCAT1 inhibitor and venetoclax resulted in higher AATK expression than BCAT1 inhibitor alone, which correlated with the enhanced cytotoxic effect on the cells. While AATK silencing at 48 hours after BCAT1 inhibitor and venetoclax combination treatment reversed the drug-induced cytotoxicity, suggesting that BCAT1/AATK/TP53-mediated apoptosis arrest contributes to the inability of venetoclax to effectively initiate apoptotic programs, thereby driving resistance.

Collectively, our findings demonstrate that BCAT1 suppresses AATK expression through TET2 inactivation, attenuates TP53 Ser366 phosphorylation, and downregulates the TP53 downstream pro-apoptotic molecules BAX and APAF1, thereby blocking the apoptotic cascade and impairing venetoclax sensitivity in NPM1mutFLT3ITD AML cells. Therapeutic targeting of BCAT1 reverses venetoclax resistance and further reduces leukemic burden. This study reveals a mechanism by which FLT3-ITD mutations drive poor outcomes in NPM1-mutated AML through BCAT1-mediated epigenetic dysregulation and apoptosis blockade. We also identify a promising therapeutic target and provide key evidence for clinical translation of BCAT1-targeted strategies in NPM1mutFLT3ITD AML.

Kainan Zhang, PhD: No relevant conflicts of interest to declare.